Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia, Journal of Clinical Oncology, vol.23, issue.22, pp.5027-5033, 2005. ,
DOI : 10.1200/JCO.2005.09.137
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe, pp.2040-2045, 2010. ,
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014. ,
DOI : 10.1200/JCO.2013.53.5229
Response Assessment of Aggressive Non-Hodgkin???s Lymphoma by Integrated International Workshop Criteria and Fluorine-18???Fluorodeoxyglucose Positron Emission Tomography, Journal of Clinical Oncology, vol.23, issue.21, pp.4652-4661, 2005. ,
DOI : 10.1200/JCO.2005.01.891
Meignan M: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large Bcell lymphoma: SUV-based assessment versus visual analysis Journal of nuclear medicine : official publication, Society of Nuclear Medicine, pp.1626-1632, 2007. ,
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. European journal of nuclear medicine and molecular imaging, pp.1312-1320, 2013. ,
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European journal of nuclear medicine and molecular imaging, pp.2017-2022, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01141151
Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.116, issue.1, pp.34-42, 2012. ,
DOI : 10.1200/JCO.2010.30.0368
URL : https://hal.archives-ouvertes.fr/hal-00673375
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008. ,
Distinct types of diffuse large B-cell lymphoma identified by gene expression
profiling, Nature, vol.303, issue.6769, pp.503-511, 2000. ,
DOI : 10.1038/35000501
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.25, pp.1937-1947, 2002. ,
DOI : 10.1056/NEJMoa012914
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.9991-9996, 2003. ,
DOI : 10.1073/pnas.1732008100
Accurate Classification of Germinal Center B-Cell???Like/Activated B-Cell???Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase???Multiplex Ligation-Dependent Probe Amplification Assay, The Journal of Molecular Diagnostics, vol.17, issue.3, 2015. ,
DOI : 10.1016/j.jmoldx.2015.01.007
URL : https://hal.archives-ouvertes.fr/hal-01145953
Aggressive lymphomas, pp.1417-1429, 2010. ,
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles, The Lancet, vol.381, issue.9880, pp.1817-1826, 2013. ,
DOI : 10.1016/S0140-6736(13)60313-X
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab, Leukemia, vol.65, issue.10, pp.1917-1924, 2008. ,
DOI : 10.1086/444428
URL : https://hal.archives-ouvertes.fr/inserm-00339565
Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22, pp.2313-2323, 2008. ,
DOI : 10.1056/NEJMoa0802885
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004. ,
DOI : 10.1182/blood-2003-05-1545
Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.1, pp.23-32, 2011. ,
DOI : 10.3816/CLML.2011.n.003
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Blood, vol.117, issue.18, pp.4836-4843, 2011. ,
DOI : 10.1182/blood-2010-12-322362
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation, Hematological Oncology, vol.28, issue.27, pp.143-149, 2012. ,
DOI : 10.1002/hon.1017
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study, Journal of Clinical Oncology, vol.29, issue.31, pp.4079-4087, 2011. ,
DOI : 10.1200/JCO.2011.35.4423
Valeur pronostique du profil d'expression génique et du PET SCAN dans les lymphomes diffus à grandes cellules de phénotype B. Thèse d'exercice pour le diplome d'état en médecine-Faculté de médecine de Rouen EANM procedure guidelines for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging, pp.181-200, 2010. ,
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, pp.1113-1122, 2014. ,
Pronostic value of Baseline Metabolic Tumor Volume (MTV0) measured on FDG PET/CT in patients with peripheral T-cell Lymphoma (PTCL), 13-ICML Oral Presentations Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma, European journal of nuclear medicine and molecular imaging 2014, pp.100-1801735, 2015. ,
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, pp.5027-5033, 2005. ,
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the ,
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.24, pp.3121-3127, 2006. ,
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, The New England journal of medicine, vol.346, pp.235-242, 2002. ,
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014. ,
DOI : 10.1200/JCO.2013.53.5229
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas ? a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial), p.391, 2014. ,
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, pp.4652-4661, 2005. ,
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, vol.107, pp.52-59, 2006. ,
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, pp.1514-1523, 2005. ,
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European journal of nuclear medicine and molecular imaging, pp.2017-2022, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01141151
Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement, Annals of Hematology, vol.74, issue.5, pp.697-703, 2012. ,
DOI : 10.1007/s00277-011-1357-2
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-511, 2000. ,
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, The New England journal of medicine, vol.346, pp.1937-1947, 2002. ,
Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22, pp.2313-2323, 2008. ,
DOI : 10.1056/NEJMoa0802885
Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma, Leukemia & lymphoma, vol.53, pp.34-42, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00673375
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.9991-9996, 2003. ,
DOI : 10.1073/pnas.1732008100
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, 2014. ,
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging, pp.1735-1743, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00998569
Revised response criteria for malignant lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.25, pp.579-586, 2007. ,
EANM procedure guidelines for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging, pp.181-200, 2010. ,
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. European journal of nuclear medicine and molecular imaging, pp.1113-1122, 2014. ,
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma, Cancer, vol.37, issue.6, pp.1195-1202, 2013. ,
DOI : 10.1002/cncr.27855
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Blood, vol.117, pp.4836-4843, 2011. ,
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials, Clinical lymphoma, myeloma & leukemia, vol.11, pp.23-32, 2011. ,
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation, Hematological Oncology, vol.28, issue.27, pp.143-149, 2012. ,
DOI : 10.1002/hon.1017
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.29, pp.4079-4087, 2011. ,
Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms, Clinical Lymphoma Myeloma and Leukemia, vol.14, issue.6, pp.460-467, 2014. ,
DOI : 10.1016/j.clml.2014.05.002
Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation- Dependent Probe Amplification Assay: A CALYM Study. The Journal of molecular diagnostics : JMD 2015, Scott DW, vol.29 ,
URL : https://hal.archives-ouvertes.fr/hal-01145953
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue, Blood, vol.123, pp.1214-1217, 2014. ,
Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification, Blood, vol.122, issue.24, pp.3884-3891, 2013. ,
DOI : 10.1182/blood-2013-05-498329
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP, Blood, vol.111, pp.5509-5514, 2008. ,
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP, Blood, vol.112, pp.3425-3433, 2008. ,
on behalf of the ESMO Guidelines Committee: Diffuse Large B-cell non-Hodgkin's lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2015. ,
Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma, Hematological oncology, issue.1, pp.3196-150, 2013. ,